Literature DB >> 15947989

Clinicopathologic features, outcome, and therapeutic interventions in four children with isolated C3 mesangial proliferative glomerulonephritis.

Kazuro Yagi1, Hidehiko Yanagida, Keisuke Sugimoto, Hiroaki Kuwajima, Nobutada Tabata, Kosuke Morita, Mitsuru Okada, Tsukasa Takemura.   

Abstract

Since isolated C3 mesangial proliferative glomerulonephritis in the absence of systemic disease (i-C3-GN) is an uncommon chronic glomerular disease, long-term prognosis and optimal therapeutic intervention for it are not yet fully defined, especially in children. We report clinical features, outcome, and interventions in 4 patients, ranging from 6 to 18 years old, with i-C3-GN. Microscopic or macroscopic hematuria with or without proteinuria was first noted between 3 and 8 years. When present, proteinuria ranged from 0.2 to 1.0 g/24 h. Persistent hypocomplementemia and circulating immune complexes were found in 1 patient. None of the patients had nephrotic syndrome or hypertension. Percutaneous renal biopsy specimens showed varying degrees of mesangial proliferative glomerulonephritis; 2 patients showed mild mesangial proliferation, while others exhibited moderate histologic severity. In 1 patient with a mild mesangial increase, tubulointerstitial changes were associated. Both patients exhibiting mild mesangial changes followed a benign clinical course with normal renal function over 10 years of follow-up. Patients with moderately severe mesangial alteration manifested slight renal function loss and moderate proteinuria at the time of biopsy, but these largely resolved after a six-month course of prednisolone combined with cyclophosphamide, warfarin, and an angiotensin-converting enzyme inhibitor. Thus, clinical manifestations and the need for aggressive treatment appear to vary among pediatric patients with i-C3-GN. Therapy combining prednisolone with immunosuppression seemed to reduce proteinuria and improve glomerular function in patients with moderately severe mesangial proliferation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947989     DOI: 10.1007/s00467-005-1919-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  15 in total

1.  Clinicopathological features in patients with isolated C3 mesangial proliferative glomerulonephritis.

Authors:  C Manno; A R Proscia; E Laraia; M Giangrande; M Di Carlo; C Salvatore; A Tasco; F P Schena
Journal:  Nephrol Dial Transplant       Date:  1990       Impact factor: 5.992

2.  Long-term follow-up of patients with isolated C3 nephritis.

Authors:  L Grcevska; M Polenakovic
Journal:  Clin Nephrol       Date:  1998-10       Impact factor: 0.975

3.  Immunofluorescent microscopy findings in minimal or no change-disease and slight generalised mesangioproliferative glomerulonephritis. Fluorescent microscopy results correlated to symptoms and clinical course.

Authors:  S Larsen
Journal:  Acta Pathol Microbiol Scand A       Date:  1978-11

4.  Mesangial isolated C3 deposition in patients with recurrent or persistent hematuria.

Authors:  C Orfila; M T Pieraggi; J M Suc
Journal:  Lab Invest       Date:  1980-07       Impact factor: 5.662

5.  Isolated C3 deposition in patients without systemic disease.

Authors:  D Grekas; A R Morley; R Wilkinson; D N Kerr
Journal:  Clin Nephrol       Date:  1984-05       Impact factor: 0.975

6.  IgA nephropathy: long-term prognosis for pediatric patients.

Authors:  R J Wyatt; S B Kritchevsky; S Y Woodford; P M Miller; S Roy; N H Holland; E Jackson; N A Bishof
Journal:  J Pediatr       Date:  1995-12       Impact factor: 4.406

7.  Long-term prognosis and prognostic indices of IgA nephropathy in juvenile and in adult Japanese.

Authors:  Y Kusumoto; S Takebayashi; T Taguchi; T Harada; S Naito
Journal:  Clin Nephrol       Date:  1987-09       Impact factor: 0.975

8.  Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.

Authors:  Kazuro Yagi; Mitsuru Okada; Hidehiko Yanagida; Hiroaki Kuwajima; Masaru Ikeda; Keisuke Sugimoto; Tsukasa Takemura
Journal:  Clin Exp Nephrol       Date:  2003-12       Impact factor: 2.801

9.  Long-term evolution of patients with isolated C3 mesangial glomerulonephritis.

Authors:  J Calls Ginesta; J Almirall; A Torras; A Darnell; L Revert
Journal:  Clin Nephrol       Date:  1995-04       Impact factor: 0.975

10.  Localization of receptors for activated complement on visceral epithelial cells of the human renal glomerulus.

Authors:  M L Shin; M C Gelfand; R B Nagle; J R Carlo; I Green; M M Frank
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

View more
  6 in total

1.  Increased plasma acylation-stimulating protein in pediatric proteinuric renal disease.

Authors:  Jin Hui Tang; Yu Wen; Fei Wu; Xiao Y Zhao; Mei X Zhang; Jie Mi; Katherine Cianflone
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

2.  Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees.

Authors:  Yiannis Athanasiou; Konstantinos Voskarides; Daniel P Gale; Loukas Damianou; Charalambos Patsias; Michalis Zavros; Patrick H Maxwell; H Terence Cook; Panayiota Demosthenous; Andreas Hadjisavvas; Kyriacos Kyriacou; Ioanna Zouvani; Alkis Pierides; Constantinos Deltas
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

Review 3.  The role of molecular genetics in diagnosing familial hematuria(s).

Authors:  Constantinos Deltas; Alkis Pierides; Konstantinos Voskarides
Journal:  Pediatr Nephrol       Date:  2011-06-19       Impact factor: 3.714

4.  Macrophage migration inhibitory factor urinary excretion revisited – MIF a potent predictor of the immunosuppressive treatment outcomes in patients with proliferative primary glomerulonephritis.

Authors:  Rafał Zwiech
Journal:  BMC Immunol       Date:  2015-08-14       Impact factor: 3.615

5.  Predictive value of conjointly examined IL-1ra, TNF-R I, TNF-R II, and RANTES in patients with primary glomerulonephritis.

Authors:  Rafał Zwiech
Journal:  J Korean Med Sci       Date:  2013-01-29       Impact factor: 2.153

6.  S-Fas urinary excretion helps to predict the immunosuppressive treatment outcomes in patients with proliferative primary glomerulonephritis.

Authors:  Rafał Zwiech
Journal:  J Korean Med Sci       Date:  2013-09-25       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.